By Carlo Martuscelli

 

Clinical-stage biotechnology business Immatics said Thursday that GlaxoSmithKline will license two of its T-cell therapy candidates being developed to treat cancer for a $50 million upfront payment.

Under the terms of the agreement, Glaxo will be responsible for developing, manufacturing and commercializing the investigative treatments. Immatics said that, in addition to the award upfront, is eligible for over $550 million in development, regulatory and commercial payments for each product, plus royalties.

The collaboration deal also includes the option for the British pharmaceutical company to license additional candidates. German biotech startup Immatics said that it is developing treatments that uses natural or engineered T-cells, a kind of immune cell, to fight solid tumors.

This latest deal brings Glaxo's cell-therapy pipeline up to six assets, from four previously. In Europe there are currently two approved cell-therapy products, both to treat certain blood cancers, developed by drug makers Gilead Science and Novartis.

 

Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu

 

(END) Dow Jones Newswires

February 20, 2020 05:14 ET (10:14 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more GlaxoSmithKline Charts.
GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more GlaxoSmithKline Charts.